A previous case of AIH has been reported after a cumulative dose of 215 mcg of IFN (beta)-1a, however this patient had taken nefazodone. 4 Another patient on IFN (beta)-1a developed AIH after 24 months. 2 The patient reported here had signs and symptoms of hepatic dysfunction after only 51 mcg of Rebif had been administered in just six doses. At the onset of treatment with IFN (beta)-1a, patients with MS should be informed about possible hepatic complications of their medication since our patient developed signs and symptoms 2 weeks before her first recommended blood test at 1 month. Second, the authors cite mortality in 10 to 15% with ALT Ͼ3 ULN and Tbili Ͼ1.6 ULN. However, the mortality associated with Hy's rule rather refers to patients with jaundice (generally Tbili Ͼ3) and ALT Ͼ 3 ULN. 7 Thus one, and possibly two (of 835 patients) had this combination while no cases were seen in 1,995 patients exposed to IFN beta-1a at various doses in clinical trials, 8 making the risk very low, though not absent.
Third, the rate of ALT increase in PRISMS is cited as 19.6% and 27.2% and the authors imply this is lower than their values due to "vague reporting style" in clinical trials. The comparison is not relevant because the values in PRISMS refer to ALT elevation considered as adverse events by the physician, not to patients with laboratory evidence of ALT elevation, as per Tremlett et al. Because ALT elevations are predominantly mild, they are often not considered as clinically relevant, nor reported as adverse events. Rates of laboratory detected ALT elevations higher than those found by Tremlett et al. have been reported, including the fact that most are mild and self-limited. 8 This suggests that the level of ascertainment in the Tremlett et al. series was less thorough, presumably due to the retrospective nature of the study, than in prospective, controlled clinical study data in which placebo comparative results are also provided.
Finally, with respect to the suggestion that acetaminophen might increase liver dysfunction in patients receiving IFN therapy, concomitant use of IFN and acetaminophen in over 700 patients was associated with reduced, not increased, risk of ALT elevation compared to patients receiving IFN alone. 8 The brief report by Tremlett Tremlett et due to exposure time and numbers of treated cases. Only when very large numbers of MS patients are treated with the licensed beta-interferons will cases such as this be reported. Pooling of such cases is then vital to facilitate the identification of emerging patterns, such as a preponderance of females developing severe hepatic injury associated with beta-interferon treatment in MS. 8 We encourage others to report such cases should they arise and also to complete an adverse drug reaction report to the relevant National Health Authority. Most of these forms are available online, including in the United States, 10 Canada, 11 and the United Kingdom. 12 We welcome the comments from Drs. Francis and Alteri (Serono; manufacturers of beta-interferon-1a [Rebif]) and Dr. Kaplowitz. Answering each point raised in order:
1. Comparing the relative potency of the beta-interferons (IFNBs) is quite a challenge. Several different options were considered before the current methodology was decided upon. Using the ranking suggested by Francis et al. does not change our results in that a dose-response effect is still observed.
2. Unfortunately, neither our post-marketing study 1 nor the pooled results from 1995 IFNB treated trial patients 8 will give a true indication of the risk of severe hepatotoxicity associated with the beta-interferons for MS. Even if the risk of serious hepatotoxicity is deemed as fairly high (i.e., 1/10,000 to 1/50,000), 13 at least 30,000 to 150,000 MS patients need to be exposed to IFNB and every single case of serious hepatotoxicity reported before the true risk will be known (the rule of 3s).
14 Again, we encourage the reporting of such cases to the relevant National Health Authorities. Since submission and acceptance of our post-marketing study, 1 another alert warning health care professionals of hepatic injury associated with IFNB was issued by Health Canada 15 in conjunction with the Pharmaceutical Manufacturers of IFNB.
3. The vague reporting style refers to this exact problem highlighted by Francis et al. It is unclear in the PRISMS clinical trial report 16 that the numbers of patients with elevated ALT were not all the patients who developed elevated ALT, rather only those who individual physicians flagged as having an adverse event. This is not a consistent, reproducible, or acceptable way to report adverse drug reactions in clinical trials. Hence there is an apparent sharp increase in the proportion of IFNB-1a (SC 44 mcg three times weekly) patients developing elevated ALT over a 2-year period-from 27.2% reported in PRISMS 16 to 67% reported in a part re-analysis of PRISMS/part pooling with other IFNB-1a clinical trials. 8 4. We hypothesized that concomitant medication, particularly acetaminophen (paracetamol), known to cause hepatotoxicity and frequently recommended to MS patients as prophylaxis against the flu-like symptoms associated with IFNB treatment, might increase the risk of hepatoxocity. 1 Francis et al. 8 were able to show that acetaminophen was not a risk factor in IFNB-treated patients developing an elevation in ALT (ϾULN), although propionic acid derivatives (including ibuprofen) did increase the risk in both the placebo and IFNB groups.
